| Accession |
PRJCA030136 |
| Title |
Camrelizumab plus apatinib for ACC |
| Relevance |
Medical |
| Data types |
Metagenome
Targeted Locus (Loci)
|
| Organisms |
Microbiota
|
| Description |
This a phase 2 trial, aiming to evaluate the activity and safety of PD-1 inhibitor (camrelizumab) plus VEGFR inhibitor (apatinib) for previously treated advanced ACC. |
| Sample scope |
Multiisolate |
| Release date |
2024-11-12 |
| Publication |
| PubMed ID |
Article title |
Journal name |
DOI |
Year |
| 39609453
|
Camrelizumab plus apatinib for previously treated advanced adrenocortical carcinoma: a single-arm phase 2 trial
|
Nature Communications
|
10.1038/s41467-024-54661-9
|
2024
|
|
|
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| Ministry of Science and Technology of the People's Republic of China (MOST)
|
|
2021YFE0206600
|
|
|
|
| Submitter |
Xingchen
Peng (pxx2014@163.com)
|
| Organization |
West China Hospital of Sichuan University |
| Submission date |
2024-09-12 |
